Clinical trial · Interventional
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life. Therapy options for multiple brain metastases may vary and range from stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), chemotherapy, immunotherapy to palliative best supportive care. Especially the efficacy and toxicity of SRS compared to WBRT in patients with extensive brain metastases (\>4) is not yet clear but of incremental relevance in this seriously ill cohort with a limited life span. These health-impaired patients might especially profit from a less toxic treatment that is also time sparing with 1 or few sessions in SRS versus 10 sessions in WBRT. On the other hand, no compromises in efficacy want to be done.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Nsclc | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SRS | Radiation | — | UNRESOLVED |
| Whole Brain Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental Treatment Arm
- description
- Best Supportive Care + Stereotactic Radiotherapy of all Brain Metastases
- interventionNames
- Radiation: SRS
- type
- OTHER
- label
- Standard Treatment Arm
- description
- Best Supportive Care ± Whole Brain Radiotherapy
- interventionNames
- Radiation: Whole Brain Radiotherapy
Primary outcomes (3)
- measure
- overall survival
- timeFrame
- time from randomisation until the date of death from any cause, assesd up to 24 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed malignant illness * 4-15 suspect intracranial lesions, taking into consideration all available MRI series * age ≥ 18 years of age * For women with childbearing potential, (and men) adequate contraception. * Ability of subject to understand character and individual consequences of the clinical trial * Written informed consent (must be available before enrolment in the trial) Exclusion Criteria: * Refusal of the patients to take part in the study * Inability to tolerate irradiation consistent with the protocol * Small-cell lung cancer (SCLC) or lymphoma as primary malignant illness * \>15 suspect intracranial lesions, taking into consideration all available MRI series * leptomeningeal disease * Previous radiotherapy of the brain * Patients who have not yet recovered from acute high-grade toxicities of prior therapies * Pregnant or lactating women * Participation in another competing clinical study or observation period of competing trials, respectively * MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)
References
Publications (0)
Data not yet available